FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara® for Hypoparathyroidism

September 10, 2014 12:04 PM

12 0

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has posted briefing materials for the September 12 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting to review the company’s Biologics License Application (BLA) for Natpara® (rhPTH[1-84]). Natpara is a bioengineered replacement therapy for endogenous parathyroid hormone (PTH) that NPS Pharma has developed for the treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of PTH.

The briefing materials can be found on the FDA website at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm386727.htm.

Read more

To category page